Company Description

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States.

Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc).

Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Chemomab Therapeutics Ltd.

Country	Israel
Founded	2004
Industry	Biotechnology
Sector	Healthcare
Employees	20
CEO	Adi George

Contact Details

Address: Building 7, Kiryat Atidim Tel Aviv, 6158002 Israel
Phone	972 77 331 0156
Website	chemomab.com

Stock Details

Ticker Symbol	CMMB
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001534248
CUSIP Number	03280X102
ISIN Number	US16385C1045
Employer ID	81-3676773
SIC Code	2834

Key Executives

Name	Position
Dr. Adi Mor George Ph.D.	Co-Founder, Chief Scientific Officer, Chief Executive Officer and Executive Director
Sigal Fattal CPA, M.B.A.	Chief Financial Officer
Barbara Lindheim	Consulting Vice President of Investor and Public Relations, Strategic Communications
Dr. David M. Weiner M.D.	Interim Chief Medical Officer
Jack Lawler	Chief Development Officer

Latest SEC Filings

Date	Type	Title
Jul 25, 2025	6-K	Report of foreign issuer
Jul 25, 2025	424B5	Filing
Jul 1, 2025	6-K	Report of foreign issuer
Jun 23, 2025	SCHEDULE 13D/A	Filing
May 27, 2025	6-K	Report of foreign issuer
May 15, 2025	6-K	Report of foreign issuer
Apr 15, 2025	6-K	Report of foreign issuer
Apr 10, 2025	SCHEDULE 13G/A	Filing
Apr 4, 2025	20-F	Annual and transition report of foreign private issuers
Mar 27, 2025	6-K	Report of foreign issuer

View All SEC Filings